UK Court Ruling A Blow For Pfizer And A Warning For Patentees
Executive Summary
A UK Supreme Court decision to invalidate Pfizer's pregabalin patent is not only bad news for Pfizer and good news for the generics firms involved – it could also mean that companies have to produce more evidence to substantiate their patent claims in future.
You may also be interested in...
BMS Plans Appeal After Sandoz And Teva Eliminate UK Eliquis Patent
While Teva and Sandoz have succeeded in having a UK court invalidate a patent and SPC protecting BMS’ Eliquis (apixaban), the originator is planning an appeal against the decision. Meanwhile, further litigation is proceeding over a separate family of Eliquis formulation patents.
UK Patent ‘Plausibility’: Landmark Lyrica Case May Get Supreme Court Ruling By Early Summer
Companies looking forward to a ruling from the Supreme Court on “plausibility” in the UK case involving second medical use patents may have to wait until May or June.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.